A Worrisome Cancer in Women—And It’s Not Breast

By Brittany | February 01, 2012 | Category: Cancer
A Worrisome Cancer in Women—And It’s Not Breast
By Barbara Gottlieb, MD, MPH
Associate Professor, Harvard Medical School; Associate Professor, Harvard School of Public Health; Brookside Community Health Center and Associate Physician, Brigham and Women's Hospital, Boston, MA

Although my patients have very diverse backgrounds (ie, in class, age, ethnicity, race, education, language, health literacy), they are quite similar in what they fear and what they don’t fear. For my female patients, breast cancer is at the top of the list. Somewhere beneath that is diabetes, then heart disease, stroke, and others that you would expect. I’m pretty sure that for most of my patients, lung cancer doesn’t even make it on the list.

[More]


Personalized Medicine: Innovation Isn’t Everything, It’s the Only Thing

By Brittany | January 25, 2012 | Category: Pharmacotherapy
Personalized Medicine: Innovation Isn’t Everything,                                                It’s the Only Thing
By Ralph Tarantino, PhD
Pharmaceutical Consultant and Principal, SteriTech Solutions, LLC
Middletown, NJ

Most would agree that mapping of the human genome during the last few years of the 20th century was a key technological advance in a century that saw the most technological advances in history. Knowledge of the human genome makes pharmacogenomics possible, and pharmacogenomics makes personalized medicines possible. Personalized medicine—hype not withstanding—is a model for pharmacotherapeutics that cannot be ignored by those interested in advancements in the treatment of disease. It most often refers to use of an individual’s genetic information to optimize treatment or prevent disease for that individual. Crizotinib (Xalkori) and vemurafenib (Zelboraf) are notable personalized medicines approved by the FDA in 2011.

[More]


When a Drug is Not a Medicine

By Admin | January 11, 2012 | Category: Pharmacotherapy
When a Drug is Not a Medicine
By Ralph Tarantino, PhD
Pharmaceutical Consultant and Principal, SteriTech Solutions, LLC
Middletown, NJ

It wasn’t all that long ago that generic drugs were the exception rather than the rule. On expiration of the innovator’s patent, there would be a somewhat gradual decline in sales due to generic competition, but a loyal following of prescribers and patients would keep the product afloat for a few years. Their faith in the brand name would be buoyed by the know-how behind the product, the innovator’s history of success, and the knowledge that there was a best-in-the-field staff of scientists and technologists who made the product possible. It was good decision making. Drug product choice is a very important decision. [More]


Month List

RecentComments

Comment RSS